Drug Type Small molecule drug |
Synonyms ABBV-722 |
Target |
Action antagonists |
Mechanism LPAR1 antagonists(Lysophosphatidic acid receptor Edg-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | Phase 1 | United States | 09 Oct 2024 | |
| Scleroderma, Systemic | Phase 1 | United States | 09 Oct 2024 |





